Q3 2025 Earnings Forecast for Travere Therapeutics, Inc. (NASDAQ:TVTX) Issued By Wedbush

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities research analysts at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Travere Therapeutics in a research note issued on Friday, September 6th. Wedbush analyst L. Chico now expects that the company will earn $0.27 per share for the quarter, up from their previous […]

Leave a Reply

Your email address will not be published.

Previous post Analyzing Community Bank System (NYSE:CBU) & Pinnacle Financial Partners (NASDAQ:PNFP)
Next post First Majestic Silver (TSE:AG) Price Target Lowered to C$7.00 at BMO Capital Markets